WeVote
Log In

Bill

Bill

HF 320

A bill for an act relating to the right to try Act.

2025-2026 Regular Session Introduced by Steve Bradley

Bill relating to Iowa's Right to Try Act enabling terminal patients to access unapproved experimental treatments was withdrawn after committee approval.

Withdrawn.
#diseases #medicalcare
0
WeVote Research Nonpartisan
Bill Summary · HF 320

Legislative bill overview

HF 320 (renumbered as HF 802) relates to Iowa's "Right to Try" Act, which typically allows terminally ill patients to access experimental drugs and treatments not yet approved by the FDA. The bill passed committee with amendments but was subsequently withdrawn on March 21, 2025, halting its progression through the legislature.

Why is this important

Right to Try laws balance patient autonomy and hope against drug safety protocols. They raise real questions about protecting vulnerable populations from false hope and unproven treatments while respecting end-of-life medical choices. The bill's withdrawal suggests either political consensus concerns or sponsor strategy changes regarding experimental treatment access in Iowa.

Potential points of contention

  • Patient safety vs. autonomy: Debate over whether terminally ill patients should access completely untested drugs without full FDA vetting, risking harm or false hope
  • Liability and pharmaceutical company concerns: Questions about manufacturer protections when providing experimental treatments and who bears responsibility for adverse outcomes
  • Equity issues: Whether Right to Try access depends on wealth, potentially creating two-tiered access to experimental treatments

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.